Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Growth (Status and Outlook) 2026-2032
The global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
United States market for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors players cover Amgen, Mirati Therapeutics, Novartis, Genentech, Verastem Oncology, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the “Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Industry Forecast” looks at past sales and reviews total world Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors sales in 2025, providing a comprehensive analysis by region and market sector of projected Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors sales for 2026 through 2032. With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors industry.
This Insight Report provides a comprehensive analysis of the global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors.
This report presents a comprehensive overview, market shares, and growth opportunities of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market by product type, application, key players and key regions and countries.
Segmentation by Type:
United States market for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors players cover Amgen, Mirati Therapeutics, Novartis, Genentech, Verastem Oncology, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the “Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Industry Forecast” looks at past sales and reviews total world Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors sales in 2025, providing a comprehensive analysis by region and market sector of projected Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors sales for 2026 through 2032. With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors industry.
This Insight Report provides a comprehensive analysis of the global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors.
This report presents a comprehensive overview, market shares, and growth opportunities of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Direct Inhibitors
- Signal transduction inhibitors
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Amgen
- Mirati Therapeutics
- Novartis
- Genentech
- Verastem Oncology
- Revolution Medicines
- Cardiff Oncology
- Immuneering Corporation
- Jacobio Pharmaceuticals
- BridgeBio Pharma
- Deciphera Pharmaceuticals
- Elicio Therapeutics
- InventisBio
- Gritstone Bio
- D3 Bio
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size (2021-2032)
2.1.2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors by Country/Region (2021, 2025 & 2032)
2.2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Segment by Type
2.2.1 Direct Inhibitors
2.2.2 Signal transduction inhibitors
2.2.3 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type
2.2.3.1 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Type (2021-2026)
2.3 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Segment by Application
2.3.1 Retail Pharmacy
2.3.2 Hospital Pharmacy
2.3.3 Online Pharmacy
2.3.4 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application
2.3.4.1 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.4.2 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Application (2021-2026)
3 KIRSTEN RAT SARCOMA VIRAL ONCOGENE HOMOLOG (KRAS) INHIBITORS MARKET SIZE BY PLAYER
3.1 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Player
3.1.1 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue by Player (2021-2026)
3.1.2 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share by Player (2021-2026)
3.2 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 KIRSTEN RAT SARCOMA VIRAL ONCOGENE HOMOLOG (KRAS) INHIBITORS BY REGION
4.1 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Region (2021-2026)
4.2 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Annual Revenue by Country/Region (2021-2026)
4.3 Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth (2021-2026)
4.4 APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth (2021-2026)
4.5 Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth (2021-2026)
4.6 Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2021-2026)
5.2 Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2021-2026)
5.3 Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Region (2021-2026)
6.2 APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2021-2026)
6.3 APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2021-2026)
7.2 Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2021-2026)
7.3 Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors by Region (2021-2026)
8.2 Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2021-2026)
8.3 Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL KIRSTEN RAT SARCOMA VIRAL ONCOGENE HOMOLOG (KRAS) INHIBITORS MARKET FORECAST
10.1 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast by Region (2027-2032)
10.1.1 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast by Region (2027-2032)
10.1.2 Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.1.3 APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.1.4 Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.1.5 Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.2 Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast by Country (2027-2032)
10.2.1 United States Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.2.2 Canada Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.2.3 Mexico Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.2.4 Brazil Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.3 APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast by Region (2027-2032)
10.3.1 China Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Forecast
10.3.2 Japan Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.3.3 Korea Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.3.4 Southeast Asia Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.3.5 India Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.3.6 Australia Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.4 Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast by Country (2027-2032)
10.4.1 Germany Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.4.2 France Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.4.3 UK Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.4.4 Italy Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.4.5 Russia Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.5 Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast by Region (2027-2032)
10.5.1 Egypt Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.5.2 South Africa Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.5.3 Israel Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.5.4 Turkey Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.6 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast by Type (2027-2032)
10.7 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
11 KEY PLAYERS ANALYSIS
11.1 Amgen
11.1.1 Amgen Company Information
11.1.2 Amgen Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
11.1.3 Amgen Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Amgen Main Business Overview
11.1.5 Amgen Latest Developments
11.2 Mirati Therapeutics
11.2.1 Mirati Therapeutics Company Information
11.2.2 Mirati Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
11.2.3 Mirati Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Mirati Therapeutics Main Business Overview
11.2.5 Mirati Therapeutics Latest Developments
11.3 Novartis
11.3.1 Novartis Company Information
11.3.2 Novartis Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
11.3.3 Novartis Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Novartis Main Business Overview
11.3.5 Novartis Latest Developments
11.4 Genentech
11.4.1 Genentech Company Information
11.4.2 Genentech Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
11.4.3 Genentech Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Genentech Main Business Overview
11.4.5 Genentech Latest Developments
11.5 Verastem Oncology
11.5.1 Verastem Oncology Company Information
11.5.2 Verastem Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
11.5.3 Verastem Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Verastem Oncology Main Business Overview
11.5.5 Verastem Oncology Latest Developments
11.6 Revolution Medicines
11.6.1 Revolution Medicines Company Information
11.6.2 Revolution Medicines Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
11.6.3 Revolution Medicines Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Revolution Medicines Main Business Overview
11.6.5 Revolution Medicines Latest Developments
11.7 Cardiff Oncology
11.7.1 Cardiff Oncology Company Information
11.7.2 Cardiff Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
11.7.3 Cardiff Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Cardiff Oncology Main Business Overview
11.7.5 Cardiff Oncology Latest Developments
11.8 Immuneering Corporation
11.8.1 Immuneering Corporation Company Information
11.8.2 Immuneering Corporation Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
11.8.3 Immuneering Corporation Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Immuneering Corporation Main Business Overview
11.8.5 Immuneering Corporation Latest Developments
11.9 Jacobio Pharmaceuticals
11.9.1 Jacobio Pharmaceuticals Company Information
11.9.2 Jacobio Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
11.9.3 Jacobio Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Jacobio Pharmaceuticals Main Business Overview
11.9.5 Jacobio Pharmaceuticals Latest Developments
11.10 BridgeBio Pharma
11.10.1 BridgeBio Pharma Company Information
11.10.2 BridgeBio Pharma Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
11.10.3 BridgeBio Pharma Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 BridgeBio Pharma Main Business Overview
11.10.5 BridgeBio Pharma Latest Developments
11.11 Deciphera Pharmaceuticals
11.11.1 Deciphera Pharmaceuticals Company Information
11.11.2 Deciphera Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
11.11.3 Deciphera Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Deciphera Pharmaceuticals Main Business Overview
11.11.5 Deciphera Pharmaceuticals Latest Developments
11.12 Elicio Therapeutics
11.12.1 Elicio Therapeutics Company Information
11.12.2 Elicio Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
11.12.3 Elicio Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Elicio Therapeutics Main Business Overview
11.12.5 Elicio Therapeutics Latest Developments
11.13 InventisBio
11.13.1 InventisBio Company Information
11.13.2 InventisBio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
11.13.3 InventisBio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 InventisBio Main Business Overview
11.13.5 InventisBio Latest Developments
11.14 Gritstone Bio
11.14.1 Gritstone Bio Company Information
11.14.2 Gritstone Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
11.14.3 Gritstone Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Gritstone Bio Main Business Overview
11.14.5 Gritstone Bio Latest Developments
11.15 D3 Bio
11.15.1 D3 Bio Company Information
11.15.2 D3 Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
11.15.3 D3 Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 D3 Bio Main Business Overview
11.15.5 D3 Bio Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size (2021-2032)
2.1.2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors by Country/Region (2021, 2025 & 2032)
2.2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Segment by Type
2.2.1 Direct Inhibitors
2.2.2 Signal transduction inhibitors
2.2.3 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type
2.2.3.1 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Type (2021-2026)
2.3 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Segment by Application
2.3.1 Retail Pharmacy
2.3.2 Hospital Pharmacy
2.3.3 Online Pharmacy
2.3.4 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application
2.3.4.1 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.4.2 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Application (2021-2026)
3 KIRSTEN RAT SARCOMA VIRAL ONCOGENE HOMOLOG (KRAS) INHIBITORS MARKET SIZE BY PLAYER
3.1 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Player
3.1.1 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue by Player (2021-2026)
3.1.2 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share by Player (2021-2026)
3.2 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 KIRSTEN RAT SARCOMA VIRAL ONCOGENE HOMOLOG (KRAS) INHIBITORS BY REGION
4.1 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Region (2021-2026)
4.2 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Annual Revenue by Country/Region (2021-2026)
4.3 Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth (2021-2026)
4.4 APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth (2021-2026)
4.5 Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth (2021-2026)
4.6 Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2021-2026)
5.2 Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2021-2026)
5.3 Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Region (2021-2026)
6.2 APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2021-2026)
6.3 APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2021-2026)
7.2 Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2021-2026)
7.3 Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors by Region (2021-2026)
8.2 Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2021-2026)
8.3 Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL KIRSTEN RAT SARCOMA VIRAL ONCOGENE HOMOLOG (KRAS) INHIBITORS MARKET FORECAST
10.1 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast by Region (2027-2032)
10.1.1 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast by Region (2027-2032)
10.1.2 Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.1.3 APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.1.4 Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.1.5 Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.2 Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast by Country (2027-2032)
10.2.1 United States Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.2.2 Canada Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.2.3 Mexico Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.2.4 Brazil Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.3 APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast by Region (2027-2032)
10.3.1 China Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Forecast
10.3.2 Japan Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.3.3 Korea Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.3.4 Southeast Asia Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.3.5 India Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.3.6 Australia Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.4 Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast by Country (2027-2032)
10.4.1 Germany Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.4.2 France Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.4.3 UK Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.4.4 Italy Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.4.5 Russia Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.5 Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast by Region (2027-2032)
10.5.1 Egypt Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.5.2 South Africa Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.5.3 Israel Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.5.4 Turkey Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
10.6 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast by Type (2027-2032)
10.7 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast
11 KEY PLAYERS ANALYSIS
11.1 Amgen
11.1.1 Amgen Company Information
11.1.2 Amgen Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
11.1.3 Amgen Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Amgen Main Business Overview
11.1.5 Amgen Latest Developments
11.2 Mirati Therapeutics
11.2.1 Mirati Therapeutics Company Information
11.2.2 Mirati Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
11.2.3 Mirati Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Mirati Therapeutics Main Business Overview
11.2.5 Mirati Therapeutics Latest Developments
11.3 Novartis
11.3.1 Novartis Company Information
11.3.2 Novartis Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
11.3.3 Novartis Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Novartis Main Business Overview
11.3.5 Novartis Latest Developments
11.4 Genentech
11.4.1 Genentech Company Information
11.4.2 Genentech Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
11.4.3 Genentech Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Genentech Main Business Overview
11.4.5 Genentech Latest Developments
11.5 Verastem Oncology
11.5.1 Verastem Oncology Company Information
11.5.2 Verastem Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
11.5.3 Verastem Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Verastem Oncology Main Business Overview
11.5.5 Verastem Oncology Latest Developments
11.6 Revolution Medicines
11.6.1 Revolution Medicines Company Information
11.6.2 Revolution Medicines Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
11.6.3 Revolution Medicines Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Revolution Medicines Main Business Overview
11.6.5 Revolution Medicines Latest Developments
11.7 Cardiff Oncology
11.7.1 Cardiff Oncology Company Information
11.7.2 Cardiff Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
11.7.3 Cardiff Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Cardiff Oncology Main Business Overview
11.7.5 Cardiff Oncology Latest Developments
11.8 Immuneering Corporation
11.8.1 Immuneering Corporation Company Information
11.8.2 Immuneering Corporation Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
11.8.3 Immuneering Corporation Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Immuneering Corporation Main Business Overview
11.8.5 Immuneering Corporation Latest Developments
11.9 Jacobio Pharmaceuticals
11.9.1 Jacobio Pharmaceuticals Company Information
11.9.2 Jacobio Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
11.9.3 Jacobio Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Jacobio Pharmaceuticals Main Business Overview
11.9.5 Jacobio Pharmaceuticals Latest Developments
11.10 BridgeBio Pharma
11.10.1 BridgeBio Pharma Company Information
11.10.2 BridgeBio Pharma Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
11.10.3 BridgeBio Pharma Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 BridgeBio Pharma Main Business Overview
11.10.5 BridgeBio Pharma Latest Developments
11.11 Deciphera Pharmaceuticals
11.11.1 Deciphera Pharmaceuticals Company Information
11.11.2 Deciphera Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
11.11.3 Deciphera Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Deciphera Pharmaceuticals Main Business Overview
11.11.5 Deciphera Pharmaceuticals Latest Developments
11.12 Elicio Therapeutics
11.12.1 Elicio Therapeutics Company Information
11.12.2 Elicio Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
11.12.3 Elicio Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Elicio Therapeutics Main Business Overview
11.12.5 Elicio Therapeutics Latest Developments
11.13 InventisBio
11.13.1 InventisBio Company Information
11.13.2 InventisBio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
11.13.3 InventisBio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 InventisBio Main Business Overview
11.13.5 InventisBio Latest Developments
11.14 Gritstone Bio
11.14.1 Gritstone Bio Company Information
11.14.2 Gritstone Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
11.14.3 Gritstone Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Gritstone Bio Main Business Overview
11.14.5 Gritstone Bio Latest Developments
11.15 D3 Bio
11.15.1 D3 Bio Company Information
11.15.2 D3 Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
11.15.3 D3 Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 D3 Bio Main Business Overview
11.15.5 D3 Bio Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Direct Inhibitors
Table 4. Major Players of Signal transduction inhibitors
Table 5. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2021-2026) & ($ millions)
Table 7. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Type (2021-2026)
Table 8. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2021-2026) & ($ millions)
Table 10. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Application (2021-2026)
Table 11. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue by Player (2021-2026) & ($ millions)
Table 12. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share by Player (2021-2026)
Table 13. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Key Players Head office and Products Offered
Table 14. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Region (2021-2026) & ($ millions)
Table 18. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Region (2021-2026)
Table 19. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue by Country/Region (2021-2026) & ($ millions)
Table 20. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share by Country/Region (2021-2026)
Table 21. Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2021-2026) & ($ millions)
Table 22. Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Country (2021-2026)
Table 23. Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2021-2026) & ($ millions)
Table 24. Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Type (2021-2026)
Table 25. Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2021-2026) & ($ millions)
Table 26. Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Application (2021-2026)
Table 27. APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Region (2021-2026) & ($ millions)
Table 28. APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Region (2021-2026)
Table 29. APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2021-2026) & ($ millions)
Table 30. APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2021-2026) & ($ millions)
Table 31. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2021-2026) & ($ millions)
Table 32. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Country (2021-2026)
Table 33. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2021-2026) & ($ millions)
Table 34. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2021-2026) & ($ millions)
Table 35. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Region (2021-2026) & ($ millions)
Table 36. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2021-2026) & ($ millions)
Table 37. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2021-2026) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors
Table 39. Key Market Challenges & Risks of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors
Table 40. Key Industry Trends of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors
Table 41. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Forecast by Region (2027-2032) & ($ millions)
Table 42. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share Forecast by Region (2027-2032)
Table 43. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Forecast by Type (2027-2032) & ($ millions)
Table 44. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Forecast by Application (2027-2032) & ($ millions)
Table 45. Amgen Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors
Table 46. Amgen Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
Table 47. Amgen Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 48. Amgen Main Business
Table 49. Amgen Latest Developments
Table 50. Mirati Therapeutics Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors
Table 51. Mirati Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
Table 52. Mirati Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 53. Mirati Therapeutics Main Business
Table 54. Mirati Therapeutics Latest Developments
Table 55. Novartis Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors
Table 56. Novartis Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
Table 57. Novartis Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 58. Novartis Main Business
Table 59. Novartis Latest Developments
Table 60. Genentech Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors
Table 61. Genentech Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
Table 62. Genentech Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. Genentech Main Business
Table 64. Genentech Latest Developments
Table 65. Verastem Oncology Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors
Table 66. Verastem Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
Table 67. Verastem Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. Verastem Oncology Main Business
Table 69. Verastem Oncology Latest Developments
Table 70. Revolution Medicines Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors
Table 71. Revolution Medicines Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
Table 72. Revolution Medicines Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. Revolution Medicines Main Business
Table 74. Revolution Medicines Latest Developments
Table 75. Cardiff Oncology Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors
Table 76. Cardiff Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
Table 77. Cardiff Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. Cardiff Oncology Main Business
Table 79. Cardiff Oncology Latest Developments
Table 80. Immuneering Corporation Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors
Table 81. Immuneering Corporation Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
Table 82. Immuneering Corporation Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Immuneering Corporation Main Business
Table 84. Immuneering Corporation Latest Developments
Table 85. Jacobio Pharmaceuticals Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors
Table 86. Jacobio Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
Table 87. Jacobio Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 88. Jacobio Pharmaceuticals Main Business
Table 89. Jacobio Pharmaceuticals Latest Developments
Table 90. BridgeBio Pharma Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors
Table 91. BridgeBio Pharma Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
Table 92. BridgeBio Pharma Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 93. BridgeBio Pharma Main Business
Table 94. BridgeBio Pharma Latest Developments
Table 95. Deciphera Pharmaceuticals Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors
Table 96. Deciphera Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
Table 97. Deciphera Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 98. Deciphera Pharmaceuticals Main Business
Table 99. Deciphera Pharmaceuticals Latest Developments
Table 100. Elicio Therapeutics Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors
Table 101. Elicio Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
Table 102. Elicio Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 103. Elicio Therapeutics Main Business
Table 104. Elicio Therapeutics Latest Developments
Table 105. InventisBio Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors
Table 106. InventisBio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
Table 107. InventisBio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 108. InventisBio Main Business
Table 109. InventisBio Latest Developments
Table 110. Gritstone Bio Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors
Table 111. Gritstone Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
Table 112. Gritstone Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 113. Gritstone Bio Main Business
Table 114. Gritstone Bio Latest Developments
Table 115. D3 Bio Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors
Table 116. D3 Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
Table 117. D3 Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 118. D3 Bio Main Business
Table 119. D3 Bio Latest Developments
Table 1. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Direct Inhibitors
Table 4. Major Players of Signal transduction inhibitors
Table 5. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2021-2026) & ($ millions)
Table 7. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Type (2021-2026)
Table 8. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2021-2026) & ($ millions)
Table 10. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Application (2021-2026)
Table 11. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue by Player (2021-2026) & ($ millions)
Table 12. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share by Player (2021-2026)
Table 13. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Key Players Head office and Products Offered
Table 14. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Region (2021-2026) & ($ millions)
Table 18. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Region (2021-2026)
Table 19. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue by Country/Region (2021-2026) & ($ millions)
Table 20. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share by Country/Region (2021-2026)
Table 21. Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2021-2026) & ($ millions)
Table 22. Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Country (2021-2026)
Table 23. Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2021-2026) & ($ millions)
Table 24. Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Type (2021-2026)
Table 25. Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2021-2026) & ($ millions)
Table 26. Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Application (2021-2026)
Table 27. APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Region (2021-2026) & ($ millions)
Table 28. APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Region (2021-2026)
Table 29. APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2021-2026) & ($ millions)
Table 30. APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2021-2026) & ($ millions)
Table 31. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2021-2026) & ($ millions)
Table 32. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Country (2021-2026)
Table 33. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2021-2026) & ($ millions)
Table 34. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2021-2026) & ($ millions)
Table 35. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Region (2021-2026) & ($ millions)
Table 36. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2021-2026) & ($ millions)
Table 37. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2021-2026) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors
Table 39. Key Market Challenges & Risks of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors
Table 40. Key Industry Trends of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors
Table 41. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Forecast by Region (2027-2032) & ($ millions)
Table 42. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share Forecast by Region (2027-2032)
Table 43. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Forecast by Type (2027-2032) & ($ millions)
Table 44. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Forecast by Application (2027-2032) & ($ millions)
Table 45. Amgen Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors
Table 46. Amgen Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
Table 47. Amgen Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 48. Amgen Main Business
Table 49. Amgen Latest Developments
Table 50. Mirati Therapeutics Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors
Table 51. Mirati Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
Table 52. Mirati Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 53. Mirati Therapeutics Main Business
Table 54. Mirati Therapeutics Latest Developments
Table 55. Novartis Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors
Table 56. Novartis Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
Table 57. Novartis Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 58. Novartis Main Business
Table 59. Novartis Latest Developments
Table 60. Genentech Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors
Table 61. Genentech Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
Table 62. Genentech Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. Genentech Main Business
Table 64. Genentech Latest Developments
Table 65. Verastem Oncology Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors
Table 66. Verastem Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
Table 67. Verastem Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. Verastem Oncology Main Business
Table 69. Verastem Oncology Latest Developments
Table 70. Revolution Medicines Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors
Table 71. Revolution Medicines Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
Table 72. Revolution Medicines Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. Revolution Medicines Main Business
Table 74. Revolution Medicines Latest Developments
Table 75. Cardiff Oncology Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors
Table 76. Cardiff Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
Table 77. Cardiff Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. Cardiff Oncology Main Business
Table 79. Cardiff Oncology Latest Developments
Table 80. Immuneering Corporation Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors
Table 81. Immuneering Corporation Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
Table 82. Immuneering Corporation Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Immuneering Corporation Main Business
Table 84. Immuneering Corporation Latest Developments
Table 85. Jacobio Pharmaceuticals Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors
Table 86. Jacobio Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
Table 87. Jacobio Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 88. Jacobio Pharmaceuticals Main Business
Table 89. Jacobio Pharmaceuticals Latest Developments
Table 90. BridgeBio Pharma Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors
Table 91. BridgeBio Pharma Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
Table 92. BridgeBio Pharma Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 93. BridgeBio Pharma Main Business
Table 94. BridgeBio Pharma Latest Developments
Table 95. Deciphera Pharmaceuticals Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors
Table 96. Deciphera Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
Table 97. Deciphera Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 98. Deciphera Pharmaceuticals Main Business
Table 99. Deciphera Pharmaceuticals Latest Developments
Table 100. Elicio Therapeutics Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors
Table 101. Elicio Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
Table 102. Elicio Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 103. Elicio Therapeutics Main Business
Table 104. Elicio Therapeutics Latest Developments
Table 105. InventisBio Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors
Table 106. InventisBio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
Table 107. InventisBio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 108. InventisBio Main Business
Table 109. InventisBio Latest Developments
Table 110. Gritstone Bio Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors
Table 111. Gritstone Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
Table 112. Gritstone Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 113. Gritstone Bio Main Business
Table 114. Gritstone Bio Latest Developments
Table 115. D3 Bio Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors
Table 116. D3 Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
Table 117. D3 Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 118. D3 Bio Main Business
Table 119. D3 Bio Latest Developments
LIST OF FIGURES
Figure 1. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Sales Market Share by Country/Region (2025)
Figure 8. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Type in 2025
Figure 10. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors in Retail Pharmacy
Figure 11. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market: Retail Pharmacy (2021-2026) & ($ millions)
Figure 12. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors in Hospital Pharmacy
Figure 13. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market: Hospital Pharmacy (2021-2026) & ($ millions)
Figure 14. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors in Online Pharmacy
Figure 15. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market: Online Pharmacy (2021-2026) & ($ millions)
Figure 16. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Application in 2025
Figure 17. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share by Player in 2025
Figure 18. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Region (2021-2026)
Figure 19. Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2021-2026 ($ millions)
Figure 20. APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2021-2026 ($ millions)
Figure 21. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2021-2026 ($ millions)
Figure 23. Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Value Market Share by Country in 2025
Figure 24. United States Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Region in 2025
Figure 29. APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Type (2021-2026)
Figure 30. APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Application (2021-2026)
Figure 31. China Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 35. India Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Country in 2025
Figure 38. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Type (2021-2026)
Figure 39. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Application (2021-2026)
Figure 40. Germany Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 41. France Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 42. UK Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Application (2021-2026)
Figure 48. Egypt Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 54. APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 55. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 57. United States Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 58. Canada Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 59. Mexico Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 60. Brazil Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 61. China Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 62. Japan Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 63. Korea Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 65. India Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 66. Australia Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 67. Germany Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 68. France Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 69. UK Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 70. Italy Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 71. Russia Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 72. Egypt Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 73. South Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 74. Israel Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 75. Turkey Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 76. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 1. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Sales Market Share by Country/Region (2025)
Figure 8. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Type in 2025
Figure 10. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors in Retail Pharmacy
Figure 11. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market: Retail Pharmacy (2021-2026) & ($ millions)
Figure 12. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors in Hospital Pharmacy
Figure 13. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market: Hospital Pharmacy (2021-2026) & ($ millions)
Figure 14. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors in Online Pharmacy
Figure 15. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market: Online Pharmacy (2021-2026) & ($ millions)
Figure 16. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Application in 2025
Figure 17. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share by Player in 2025
Figure 18. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Region (2021-2026)
Figure 19. Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2021-2026 ($ millions)
Figure 20. APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2021-2026 ($ millions)
Figure 21. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2021-2026 ($ millions)
Figure 23. Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Value Market Share by Country in 2025
Figure 24. United States Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Region in 2025
Figure 29. APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Type (2021-2026)
Figure 30. APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Application (2021-2026)
Figure 31. China Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 35. India Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Country in 2025
Figure 38. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Type (2021-2026)
Figure 39. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Application (2021-2026)
Figure 40. Germany Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 41. France Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 42. UK Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Application (2021-2026)
Figure 48. Egypt Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 54. APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 55. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 57. United States Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 58. Canada Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 59. Mexico Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 60. Brazil Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 61. China Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 62. Japan Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 63. Korea Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 65. India Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 66. Australia Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 67. Germany Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 68. France Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 69. UK Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 70. Italy Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 71. Russia Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 72. Egypt Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 73. South Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 74. Israel Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 75. Turkey Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
Figure 76. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 ($ millions)
